Composition helpful for controlling in-vivo fat and application thereof

Abstract

The invention discloses a composition helpful for controlling in-vivo fat and application thereof, and relates to the technical field of biology. The hesperidin composition is prepared from hesperidin and lactobacillus johnsonii (Lactobacillus johnsonii), and the hesperidin composition is prepared from the hesperidin and the lactobacillus johnsonii. Research finds that the composition can achieve synergistic up-regulation of gene and protein expression of adipose tissue PGC1alpha and UCP1 and increase the body surface temperature; the composition can also significantly improve the bioavailability of hesperidin and improve the concentration of hesperetin and other metabolites in serum; the composition can also optimize the intestinal microecology, improve the intestinal flora structure, increase the lactobacillus colonization rate, enrich the abundance of beneficial bacteria and promote the generation of short-chain fatty acids; the composition can also significantly improve lipid metabolism disorder of an organism, reduce fat accumulation, regulate adiponectin and leptin levels, control fat in the body and realize effective weight loss management.

Description

TECHNICAL FIELD

[0001] The present application relates to the field of biotechnology, in particular to a composition for helping to control body fat and its application. BACKGROUND

[0002] In recent years, activating thermogenic pathways in adipose tissue (such as inducing white adipose tissue to express uncoupling protein UCP1) has become a new strategy for intervention in various metabolic syndrome diseases. In the mitochondria of thermogenic fat, the electron transport chain is uncoupled from the ATP synthesis pathway for heat production. UCP1 mediates the passage of protons across the inner mitochondrial membrane, dissipating the proton (H + ) gradient, thereby generating heat. By activating the expression of UCP1 and other thermogenic-related genes and proteins, the purpose of reducing body fat and resisting obesity and its metabolic syndrome can be achieved. However, the development of drugs to promote brown fat activation and white fat browning has not made substantial progress. Existing technologies mainly achieve the activation of thermogenic pathways through the following ways: ① Cold exposure or exercise: brown fat is activated or beige fat is induced through sympathetic nerves, but there are problems such as high difficulty in implementation and low compliance. ② Drug target activation: such as β3-adrenergic receptor agonists, but there is a risk of inducing cardiovascular diseases. ③ Such as capsaicin, resveratrol, etc., which have low bioavailability and require high doses (> 100 mg / kg), limiting their practical application. ④ Probiotic intervention: certain strains (such as animal bifidobacterium) can slightly increase UCP1 expression, but the efficiency is limited and it is difficult to colonize in the gut.

[0003] In addition, the current research in this field also has the following limitations: ① Poor effect of single component: a large number of research results show that hesperidin, one of the most abundant flavonoids in citrus, has little effect on the activation of thermogenic-related functional pathways, which may be caused by its very low bioavailability; the effect of Lactobacillus johnsonii alone on the regulation of host thermogenic pathways is unknown, and it needs to overcome problems such as easy loss of activity and difficulty in colonizing the gut. ② Lack of synergy in combination scheme: unselected probiotics have low metabolic conversion efficiency, and simple combination of probiotics and flavonoids cannot exhibit a synergistic effect on improving health. ③ Unclear mechanism: existing technologies cannot achieve efficient expression of UCP1 protein and significant increase of core body temperature, and lack evidence of synergistic activation of thermogenesis through strain-specific metabolic conversion (such as the axis of hesperidin→hesperetin→UCP1).

[0004] Based on the above three technical bottlenecks that need to be solved, the present application aims to develop a synergistic composition to improve the bioavailability of hesperidin and synergistically enhance the expression of key thermogenic genes and proteins, providing a new solution for the metabolic health improvement strategy targeting the "gut microbiota-host metabolic axis". SUMMARY

[0005] The present application aims to provide a composition for helping to control body fat and its application, so as to solve the problems existing in the prior art. The composition provided by the present application activates the heat production pathway through the "microbiota-host metabolic axis" linkage mechanism, thereby controlling body fat and achieving the purpose of synergistically improving the metabolic health of the body.

[0006] To achieve the above-mentioned purpose, the present application provides the following solutions:

[0007] The present application provides a composition for helping to control body fat, comprising hesperidin and Lactobacillus Johnsonii.

[0008] Further, the ratio of the hesperidin and the Lactobacillus Johnsonii is (20-30) mg: 1x10 9 CFU.

[0009] Preferably, the ratio of the hesperidin and the Lactobacillus Johnsonii is 25 mg: 1x10 9 CFU.

[0010] The present application also provides the use of the above-mentioned composition in the preparation of a product for helping to control body fat, wherein the product is a drug or a health food.

[0011] The present application also provides a drug for helping to control body fat, wherein the active ingredient comprises the above-mentioned composition.

[0012] Further, the drug further comprises a pharmaceutically acceptable excipient.

[0013] Further, the dosage form of the drug comprises oral liquid, granules, tablets, capsules, pills or powder.

[0014] The present application also provides a health food for helping to control body fat, wherein the active ingredient comprises the above-mentioned composition.

[0015] Further, the health food further comprises a food excipient.

[0016] Further, the dosage form of the health food is oral liquid, granules, capsules, powder or tablets.

[0017] The present application discloses the following technical effects:

[0018] The composition provided by the application activates the heat production pathway through the "microbiota-host metabolic axis" linkage mechanism, thereby controlling the body fat and achieving the purpose of synergistically improving the metabolic health of the body. Specifically, the composition can achieve synergistic up-regulation of the gene and protein expression of PGC1 alpha and UCP1 in adipose tissue, and increase the body surface temperature; the composition can also significantly improve the bioavailability of hesperidin, and increase the concentration of hesperetin and other metabolites in serum; the composition can also optimize the intestinal microecology, improve the intestinal flora structure, increase the colonization rate of lactobacilli, enrich the abundance of beneficial bacteria, and promote the generation of short-chain fatty acids; the composition can also significantly improve the body fat metabolism disorder, reduce fat accumulation, regulate the levels of adiponectin and leptin, control the body fat, and achieve effective weight loss management. BRIEF DESCRIPTION OF DRAWINGS

[0019] In order to more clearly illustrate the technical solutions in the embodiments of the present application or the prior art, the drawings needed in the embodiments will be briefly introduced below. Obviously, the drawings in the following description are only some embodiments of the present application, and other drawings can also be obtained by those skilled in the art without creative labor.

[0020] Figure 1 The figure is the detection result of the body surface infrared thermal imaging and the expression amount of heat production related genes and proteins (PGC1 alpha and UCP1); wherein a is a representative figure of in vitro infrared thermal imaging; b is a statistical figure of the average body surface core temperature of each group; c and d are respectively statistical figures of the gene expression level of PGC1 alpha and UCP1 in inguinal white adipose tissue (iWAT); e is a figure of the Western blot analysis result of PGC1 alpha and UCP1 in iWAT; f and g are respectively statistical figures of the protein expression level of PGC1 alpha and UCP1;

[0021] Figure 2 The figure is a serum non-targeted metabolomics analysis figure of hesperidin metabolites; wherein a is an abundance figure of hesperetin in serum of each group of mice; b is an abundance figure of hesperetin-3'-O-sulfate;

[0022] Figure 3 The figure is a detection result figure of the influence of the composition of the present application on the intestinal flora structure and the abundance of lactobacilli; wherein a is a PCA analysis figure of the intestinal flora structure; b is a relative proportion figure of the genus lactobacillus; c is a figure of the analysis result of the difference between groups;

[0023] Figure 4Figure for detection results of the effect of the composition of the present application on liver fat accumulation and adipocyte size; wherein a is the oil red O staining figure of liver section; b is the fat accumulation proportion analyzed according to the liver oil red O staining condition; c is the H&E staining result figure of the inguinal white adipose section; d is the average adipocyte size determined according to the H&E staining condition analysis;

[0024] Figure 5 Figure for detection results of serum adiponectin / leptin levels and SCFAs content in feces of each experimental group; wherein a and b are respectively the statistical figure of adiponectin level and leptin level in serum; c-i are respectively the statistical figure of total SCFAs, acetic acid, propionic acid, butyric acid, isobutyric acid, valeric acid and isovaleric acid content in feces;

[0025] Figure 6 Figure for detection results of body weight management parameters of each experimental group; wherein a is the curve figure of body weight change of the model group, hesperetin group, johnson lactobacillus group and hesperetin-johnson lactobacillus combined action group; b is the statistical figure of the final body weight growth rate of the model group, hesperetin group, johnson lactobacillus group and hesperetin-johnson lactobacillus combined action group; c is the curve figure of body weight change of the model group, hesperetin group, roe's lactobacillus group and hesperetin-roe's lactobacillus combined action group; d is the statistical figure of the final body weight growth rate of the model group, hesperetin group, roe's lactobacillus group and hesperetin-roe's lactobacillus combined action group. DETAILED DESCRIPTION

[0026] The various illustrative embodiments of the present application will now be described in detail below, which should not be considered limiting on the present application, but rather as a description of certain aspects, features and embodiments of the present application.

[0027] It should be understood that the terms used in the present application merely describe particular embodiments and are not intended to limit the present application. In addition, for the numerical range in the present application, it should be understood that each intermediate value between the upper limit and the lower limit of the range is also specifically disclosed. Each smaller range between any stated value or stated range, and any other stated value or intermediate value in the stated range, is also encompassed within the present application. The upper limit and the lower limit of these smaller ranges can be independently included or excluded from the range.

[0028] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this application belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present application, preferred methods and materials are described. All documents mentioned herein are incorporated by reference to disclose and describe the methods and / or materials in connection with which the documents are cited. In case of conflict, the content of the present specification will control.

[0029] Many modifications and variations of the present application described in the specification are possible without departing from the scope or spirit of the application. Other implementations of the application will be apparent to those skilled in the art from consideration of the specification and practice of the application disclosed herein. The specification and examples are illustrative only.

[0030] As used herein, the terms "comprises", "comprising", "includes", "including", "has", "having", "contains", "containing", or variations thereof, are intended to be open-ended terms that mean inclusion, but not limited to, the listed material or step.

[0031] Lactobacillus Johnsonii and Lactobacillus reuteri used in the following examples were purchased from Guangdong Microbial Culture Collection Center (GDMCC), with strain numbers GDMCC 1.730 and GDMCC 1.614, respectively.

[0032] The hesperidin referred to in the present application has a CAS number of 520-26-3, a molecular formula of C 28 H 34 O 15 , and a structural formula as follows:

[0033]

[0034] Example 1: Effect of the composition of the present application on the body's heat production capacity

[0035] (1) Grouping and intervention

[0036] Forty 6-8 week old C57 / BL6J mice were randomly divided into four groups, with 10 mice in each group. The grouping was set as follows: model group (HFD), hesperidin group (HEP), Lactobacillus Johnsonii group (L.J), and hesperidin-Lactobacillus Johnsonii combined action group (HEP-L.J).

[0037] The mice in each group were given different intervention methods, respectively:

[0038] The mice in the model group were given high-fat feed (60% fat energy supply of purified type) and 0.2 mL of PBS solution was given by gavage every day;

[0039] The mice in the hesperidin group were given high-fat feed containing 0.5% hesperidin and 0.2 mL of PBS solution was given by gavage every day;

[0040] The mice in the Lactobacillus Johnsonii group were given high-fat feed and 0.2 mL of bacterial suspension containing 5x10 9 CFU / mL of Lactobacillus Johnsonii was given by gavage every day;

[0041] Hesperidin- L. johnsonii combination group mice were given high-fat feed containing 0.5% hesperidin and 0.2 mL of 5 x 10 9 CFU / mL of L. johnsonii bacterial suspension.

[0042] The mice ate about 5 g of food per day, which was equivalent to about 25 mg of hesperidin intake per day, so the composition ratio used in this example was 1 mg: 4 x 10 7 CFU (hesperidin: L. johnsonii). The mice in each group were allowed to freely take food and water, and the temperature in the feeding room was 20-26°C, the relative humidity was 40-70%, the noise was less than 60 dB, and the light cycle was 12 h light and 12 h dark.

[0043] (2) Index detection

[0044] The mice in each group were raised according to the grouping and intervention mode, and the raising time was 6 weeks. On the last day of the experiment, the mice were measured for body temperature and images were obtained using an infrared thermal imager. After the mice were anesthetized, blood was taken, and the inguinal beige adipose tissue iWAT was collected. After total RNA and protein were extracted from iWAT, QPCR and Western Blot detection were performed, respectively, to analyze the gene expression and protein expression levels of PGC1α and UCP1.

[0045] (3) Experimental results

[0046] The infrared thermal imaging images and key gene and protein detection can directly reflect the activation of the thermogenic pathway in the bodies of mice with different interventions, and the results are shown in Figure 1 After 6 weeks of different interventions, only the core body temperature of the mice in the HEP-L.J group showed a significant increase, about 1°C higher than that in the other groups. In addition, the gene expression and protein expression of PGC1α and UCP1 in the inguinal white adipose tissue of the mice in the HEP-L.J group were significantly up-regulated (2-3 times), and were significantly higher than those in the HFD group, the HEP group and the L.J group.

[0047] The results show that hesperidin and L. johnsonii have a synergistic effect on activating the body's thermogenesis.

[0048] Example 2 Effect of the composition of the application on the bioavailability of hesperidin

[0049] (1) Grouping and intervention

[0050] The grouping and intervention mode were the same as in Example 1.

[0051] (2) Index detection

[0052] Each group of mice was fed according to the grouping and intervention mode, and the feeding time was 6 weeks. On the last day of the experiment, each group of mice was fasted for 10 hours without water. The mice were anesthetized, and blood was taken, and serum was obtained after centrifugation for non-targeted metabolomics analysis of hesperidin metabolites.

[0053] (3) Experimental results

[0054] The relative abundance of the main metabolites of hesperidin in the serum of mice in different groups is shown in Figure 2 . Hesperitin and its conjugates are the main metabolites. Due to the low bioavailability of hesperidin, the content of its metabolites is not high in the serum of HEP group mice. The supplementation of L.J accelerates the metabolism of hesperidin and improves the bioavailability of hesperidin. Specifically, the abundance of hesperitin and hesperitin-3'-O-sulfate in the serum of HEP-L.J group mice is significantly improved, which is about 5 times and 2.7 times higher than that of HEP group, respectively.

[0055] Example 3 Effect of the composition of the present application on the composition of intestinal flora

[0056] (1) Grouping and intervention

[0057] The grouping and intervention mode are the same as in Example 1.

[0058] (2) Index detection

[0059] Each group of mice was fed according to the grouping and intervention mode, and the feeding time was 6 weeks. On the last day of the experiment, the feces of mice were collected for 16S rDNA sequencing to analyze the composition and abundance of intestinal flora.

[0060] (3) Experimental results

[0061] As shown in Figure 3 , HEP-L.J combined intervention significantly improved the structure of intestinal flora, and the effect was different from that of HFD group, HEP group and L.J group. Compared with HEP group and L.J group, HEP-L.J combined intervention more significantly increased the abundance of Lactobacillus, and had a synergistic effect of promoting proliferation. In addition, the combined intervention of HEP-L.J also promoted the growth of other beneficial bacteria, such as Ligilactobacillus.

[0062] The above results show that the composition of the present application has a significant regulating effect on promoting the colonization and proliferation of beneficial bacteria such as Lactobacillus, and optimizing the structure of intestinal flora.

[0063] Example 4 Effect of the composition of the present application on liver and adipose tissue

[0064] (1) Grouping and intervention

[0065] Grouping and intervention mode are the same as in Example 1.

[0066] (2) Index detection

[0067] On the last day of the experiment, the mice in each group were subjected to 10 hours of fasting without water. After the mice were anesthetized, dissection was performed, and adipose tissue and liver were collected. Among them, the liver was fixed with 4% paraformaldehyde, and then sectioning and oil red O staining were performed; the inguinal white adipose tissue iWAT was fixed, and then sectioning and H&E staining were performed.

[0068] (3) Experimental results

[0069] The effects of HEP-L.J combined intervention on liver fat accumulation and adipose tissue size are shown in Figure 4 The results show that HEP-L.J combined intervention can significantly reduce fat accumulation in the liver, and the oil red O staining area ratio is reduced by about 40% compared with the model group. HEP-L.J combined intervention also significantly reduces the size of inguinal white adipose cells, showing a synergistic improvement effect compared with HEP and L.J intervention.

[0070] Example 5 Effects of the composition of the present application on serum adipokines and intestinal short-chain fatty acids

[0071] (1) Grouping and intervention

[0072] Grouping and intervention mode are the same as in Example 1.

[0073] (2) Index detection

[0074] On the last day of the experiment, the mice in each group were subjected to 10 hours of fasting without water. After the mice were anesthetized, dissection was performed, and adipose tissue and liver were collected. Among them, the liver was fixed with 4% paraformaldehyde, and then sectioning and oil red O staining were performed; the inguinal white adipose tissue iWAT was fixed, and then sectioning and H&E staining were performed.

[0075] (3) Experimental results

[0076] Obesity induced by a high-fat diet often causes leptin resistance, reduced adiponectin levels, and reduced levels of short-chain fatty acids in the intestine. Figure 5 The results show that only HEP-L.J combined intervention can significantly increase adiponectin levels and reduce leptin levels. In addition, HEP-L.J combined intervention also significantly increases the content of short-chain fatty acids in feces, especially in promoting the generation of total short-chain fatty acids, propionic acid, butyric acid, isobutyric acid, valeric acid, and isovaleric acid.

[0077] Example 6 Effects of the composition of the present application and the comparative composition on body weight management

[0078] Experimental grouping: 60 C57 / BL6J mice aged 6-8 weeks were randomly divided into 6 groups, 10 mice in each group. The groups were set as follows: model group (HFD), hesperidin group (HEP), L. johnsonii group (L.J), hesperidin-L. johnsonii combination group (HEP-L.J), L. reuteri group (L.R) and hesperidin-L. reuteri combination group (HEP-L.R).

[0079] Each group of mice was given different intervention methods:

[0080] The mice in the model group were given high-fat feed and 0.2 mL of PBS solution by gavage every day;

[0081] The mice in the hesperidin group were given high-fat feed containing 0.5% hesperidin and 0.2 mL of PBS solution by gavage every day;

[0082] The mice in the L. johnsonii group were given high-fat feed and 0.2 mL of bacterial suspension containing 5x10 9 CFU / mL of L. johnsonii by gavage every day;

[0083] The mice in the hesperidin-L. johnsonii combination group were given high-fat feed containing 0.5% hesperidin and 0.2 mL of bacterial suspension containing 5x10 9 CFU / mL of L. johnsonii by gavage every day;

[0084] The mice in the L. reuteri group were given high-fat feed and 0.2 mL of bacterial suspension containing 5x10 9 CFU / mL of L. reuteri by gavage every day;

[0085] The mice in the hesperidin-L. reuteri combination group were given high-fat feed containing 0.5% hesperidin and 0.2 mL of bacterial suspension containing 5x10 9 CFU / mL of L. reuteri by gavage every day.

[0086] The mice ate about 5g of food per day, which was equivalent to an intake of about 25mg of hesperidin per day. Each group of mice freely ingested food and water, the temperature in the feeding room was 20-26℃, the relative humidity was 40-70%, the noise was less than 60dB, and the light cycle was 12h light and 12h dark.

[0087] Index detection and results: each group of mice was raised according to the grouping and intervention methods, and the body weight of the mice was measured every week. The results, as shown in Figure 6 L. johnsonii combined with hesperidin (HEP-L.J) group significantly reduced the body weight, and the effect was stronger than that of the single group. However, under the same dose, L. reuteri combined with hesperidin (HEP-L.R) group did not show a synergistic effect on body weight management.

[0088] The results of the study show that the body weight management synergistic effect is unique to L. johnsonii and hesperidin.

[0089] Example 7 Application of the composition of the present application in oral liquid

[0090] A method for preparing an oral liquid that helps control body fat:

[0091] (1) Bacterial culture: L. johnsonii was inoculated into MRS liquid medium and cultured anaerobically at 37°C for 48 hours.

[0092] (2) Bacterial collection: After centrifugation (4°C, 6000 x g, 10 min), the supernatant was discarded, and the bacteria were resuspended in a phosphate buffer at pH 5.0; the bacterial suspension was centrifuged again (4°C, 6000 x g, 10 min), and after removing the residual culture medium, the bacteria were resuspended again in a phosphate buffer at pH 5.0 containing 10% food-grade trehalose to obtain the bacterial suspension mother liquor.

[0093] (3) Compounding: Hesperidin naturally extracted from orange peel (food grade, purity ≥ 98%) was mixed with the bacterial suspension, and the viable bacterial count was adjusted to 10 9 CFU / mL, and the content of hesperidin was 25 mg / mL to prepare an oral liquid.

[0094] (4) Packaging: After standardized production, the prepared oral liquid was aseptically packaged, packaged separately, and labeled with product labels.

[0095] (5) Quality control: An appropriate amount of oral liquid was diluted by gradient dilution, spread on MRS agar medium plates, and incubated at 37°C in an anaerobic environment for 48 hours to calculate the total number of viable bacteria in the oral liquid; the viable bacteria decay kinetics under different storage temperatures were detected to verify the stability of the oral liquid; an appropriate amount of oral liquid was extracted with methanol-DMSO solution, analyzed by high performance liquid chromatography (C18 column, methanol-0.1% formic acid water gradient elution method, detection wavelength 283 nm), and the actual content of hesperidin in the oral liquid was calculated according to the standard curve of different concentrations.

[0096] Example 8

[0097] The same as Example 7, except that in step (3), the content of hesperidin in the oral liquid was adjusted to 20 mg / mL.

[0098] Example 9

[0099] The same as Example 7, except that in step (3), the content of hesperidin in the oral liquid was adjusted to 30 mg / mL.

[0100] Example 10 Application of the composition of the present application in capsules

[0101] (1) Bacterial culture: Lactobacillus johnsonii was inoculated into MRS liquid medium and cultured anaerobically at 37°C for 48 hours.

[0102] (2) Bacterial collection: After centrifugation (4°C, 6000 x g, 10 min), the supernatant was discarded, and the bacterial cells were resuspended in phosphate buffer at pH 5.0. After centrifugation again (4°C, 6000 x g, 10 min), the residual medium was removed, and the bacterial cells were resuspended in phosphate buffer at pH 5.0 containing 10% skim milk and 5% trehalose to obtain the mother liquor of the bacterial suspension.

[0103] (3) Bacterial freeze-drying: The bacterial suspension was subjected to freeze-drying to obtain Lactobacillus johnsonii freeze-dried powder.

[0104] (4) Bacterial survival rate detection: An appropriate amount of freeze-dried powder was configured into a bacterial suspension, which was gradiently diluted, spread on MRS agar medium plates, and incubated at 37°C in an anaerobic environment for 48 hours. The total number of viable bacteria in the freeze-dried powder was determined, and the freeze-drying survival rate was calculated.

[0105] (5) Mixed filling: Hesperidin was subjected to ultrafine grinding to obtain hesperidin micro-powder with a particle size of ≤50 μm. The hesperidin micro-powder was mixed with the freeze-dried bacterial powder, and filled into hydroxypropyl methylcellulose enteric-coated capsules, with each capsule containing 25 mg of hesperidin and 10 9 CFU).

[0106] (6) Packaging: The filled capsules were aseptically divided and packaged into independent small packages, and product labels were attached.

[0107] (7) Quality control: An appropriate amount of capsule content was configured into a suspension, which was gradiently diluted, spread on MRS agar medium plates, and incubated at 37°C in an anaerobic environment for 48 hours. The total number of viable bacteria in the capsule was calculated. An appropriate amount of the suspension was extracted with a methanol-DMSO solution, and analyzed by high performance liquid chromatography (C18 column, methanol-0.1% formic acid water gradient elution method, detection wavelength 283 nm). The actual hesperidin content in the capsule was calculated according to the standard curve of different concentrations.

[0108] Example 11

[0109] The same as Example 10, except that in step (5), the hesperidin content in each capsule was adjusted to 20 mg.

[0110] Example 12

[0111] The same as Example 10, except that in step (5), the hesperidin content in each capsule was adjusted to 30 mg.

[0112] Example 13 Application of the composition of the present application in a functional solid beverage

[0113] (1) Formula composition: the formula contains 8 parts of composition powder (containing hesperidin 40 mg / g + Lactobacillus johnsonii freeze-dried powder 2 x 10 9 CFU / g), 65 parts of malt dextrin, 15 parts of resistant dextrin, 10 parts of natural orange powder and 2 parts of sucralose.

[0114] (2) Preparation process: hesperidin micro-powder and Lactobacillus johnsonii freeze-dried powder are prepared according to the method of Example 10, and then mixed at a mass ratio of 1:50 to obtain composition powder (containing hesperidin 40 mg / g + Lactobacillus johnsonii freeze-dried powder 2 x 10 9 CFU / g); the composition powder and the formula amount of malt dextrin and resistant dextrin are put into a V-type mixer and mixed at 15 rpm for 15 minutes; after mixing, the powder is sieved through an 80-mesh sieve, and the formula amount of natural orange powder and sucralose is added for seasoning, and then put into the mixer for secondary mixing; after thorough mixing, aluminum foil bags are used for packaging, each bag contains 10 g, and nitrogen is filled for airtight sealing.

[0115] (3) Quality control: the viable cell count detection and the hesperidin content detection are the same as those of Example 10.

[0116] Example 14

[0117] The same as Example 13, except that the hesperidin content in the composition powder is adjusted to 50 mg / g.

[0118] Example 15

[0119] The same as Example 13, except that the hesperidin content in the composition powder is adjusted to 60 mg / g.

[0120] The above examples only describe the preferred modes of the present application, and do not limit the scope of the present application. Without departing from the design spirit of the present application, various modifications and improvements to the technical solutions of the present application made by those skilled in the art shall fall within the protection scope determined by the claims of the present application.

Claims

1. A composition for aiding in the control of body fat, characterized by comprising, The active ingredient comprises hesperidin and Lactobacillus Johnsonii.

2. The composition of claim 1, wherein, The ratio of the hesperidin and the L. johnsonii is (20-30) mg: 1 x 10 9 CFU.

3. The composition of claim 2, wherein, The ratio of the hesperidin and the L. johnsonii is 25 mg: 1 x 10 9 CFU.

4. Use of a composition according to any one of claims 1 to 3 for the manufacture of a product for aiding the control of body fat, characterised in that, The product is a medicine or a health food.

5. A medicament useful for controlling body fat, characterized by comprising a compound of the formula (I) as an active ingredient. The active ingredient comprises the composition of any one of claims 1-3.

6. The medicament according to claim 5, characterized in that, The medicine further comprises a pharmaceutically acceptable excipient.

7. The medicament according to claim 6, characterized in that, The dosage form of the medicine comprises an oral solution, granules, tablets, capsules, pills, or powder.

8. A health food for assisting in controlling body fat, characterized by comprising the compound according to any one of claims 1 to 7. The active ingredient comprises the composition of any one of claims 1-3.

9. The health food according to claim 8, characterized by, The health food further comprises a food excipient.

10. The health food according to claim 9, characterized in that, The dosage form of the health food is an oral solution, granules, capsules, powder, or tablets.

Images